Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay

Undetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like o...

Descripción completa

Detalles Bibliográficos
Autores principales: Farren, Timothy W., Sadanand, Kaushik S., Agrawal, Samir G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744938/
https://www.ncbi.nlm.nih.gov/pubmed/33344247
http://dx.doi.org/10.3389/fonc.2020.597730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744938/
https://www.ncbi.nlm.nih.gov/pubmed/33344247
http://dx.doi.org/10.3389/fonc.2020.597730

Ejemplares similares